Phathom Pharmaceuticals vs Syndax Pharmaceuticals
PHAT and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAT and SNDX compare
Syndax Pharmaceuticals is the larger company, worth 1.7 times as much as Phathom Pharmaceuticals ($844M against $493M).
Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 86.8% for Phathom Pharmaceuticals).
Phathom Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −30.2% compared with −72.3% at Syndax Pharmaceuticals.
Phathom Pharmaceuticals scores higher on the StockData Score (4 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAT | SNDX |
|---|---|---|
| Size and price | ||
| Market cap | $493M | $844M |
| Share price | $6.06 | $9.45 |
| Change, 1 year | −58.5% | −43.7% |
| Change, 5 years | −69.8% | −46.8% |
| Beta (5Y) | 1.63 | 1.07 |
| Employees | 371 | 298 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 2.9× |
| FCF yield | −4.3% | – |
| Growth | ||
| Revenue growth (TTM) | 86.8% | 160% (better) |
| Revenue growth, 5Y average | – | 158% |
| Profitability | ||
| Gross margin | 80.7% | – |
| Operating margin | −9.3% (better) | −61.7% |
| Net margin | −30.2% (better) | −72.3% |
| FCF margin | −7.7% | – |
| Return on equity | – | −426% |
| Financial health | ||
| Interest coverage | −0.4× (better) | −44660.0× |
| Current ratio | 1.76 | 4.69 (better) |
| Altman Z-score | −4.83 | −2.28 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 88.7% | 121% |
| Held by insiders | 12.2% | 1.8% |
| Insider net buying, 12 months | $0 (better) | −$2.9M |
| Short interest, % of float | 12.9% | 21.6% |
Go deeper
- PHAT stock overview
- PHAT income statement
- PHAT valuation and score
- SNDX stock overview
- SNDX income statement
- SNDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.